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Human glomeruli release fatty acids which stimulate thromboxane
synthesis in platelets. The cell—free medium of isolated human glomeruli
exhibited a procoagulant activity and stimulated thromboxane (TXB2)
synthesis in human platelets in a dose—dependent manner. The amount
of TXB2 measured was 16-fold higher than what could have been
predicted (TXB2 synthesized by the platelets under control conditions
plus TXB2 present in the glomerular supernatant). The lipid extract of
the glomerular supernatant and its purified fraction including the fatty
acids was still able to stimulate—although at a lesser degree—TXB2
synthesis in platelets. Stimulation was abolished after treatment of this
fraction by charcoal or albumin. Gas chromatography/mass spectrom-
etry analysis demonstrated the presence in the purified glomerular
fraction of several long—chain saturated or monoenoic fatty acids at a
total concentration of 80 M with the following order of abundance:
stearic, palmitic, myristic and oleic acids. Addition to human platelets
of these same exogenous synthetic acids resulted in a dose-dependent
stimulation of TX synthesis. It was maximum with three or four fatty
acids tested in combination, but still present with myristic acid used
separately. Arachidonic acid was absent in the glomerular supernatant,
Thus the stimulation observed could not be related to a greater
availability of substrate. Fatty acids did not act on platelets through a
non-specific detergent effect since addition of high doses of detergents
inhibited TXB2 formation in platelets. The combination of fatty acids
from glomerular origin identified in the present study represents a novel
factor involved in the control of intracapillary hemostasis, but different
from the procoagulant activity common to many tissues. It is hypoth-
esized that in vivo damage of the glomerular cells could release
saturated and monoenoic fatty acids able to activate platelet functions
independently of collagen, and thus result in the local accumulation of
TXA2.
It has been recently reported that rat glomeruli contain a
procoagulant activity (PCA) identified as a membrane—bound or
a "tissue—factor"—like lipoprotein [1]. This ubiquitous factor
which exists in a dormant state on the surface of the cells is
released when cells are exposed to various stimuli such as
endotoxins [2], proteolytic enzymes [3] or mechanical disrup-
tion [1, 4]. PCA, like thromboplastin, forms an enzymatically
active complex with factor VII which activates factor X and
converts prothrombin to thrombin.
In the glomerular tuft, platelets circulate in close contact with
the capillary endothelium whose integrity is essential to avoid
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their activation. They are triggered whenever they get into
contact with strips of collagen of the damaged endothelium.
However, the possibility that apart PCA and collagen, other
diffusible factors might be released by damaged cells and might
affect arachidonic acid (AA) metabolism in platelets had never
been considered as yet.
In this report, we demonstrate that human glomeruli release,
in addition to PCA, a factor which strongly stimulates platelet
thromboxane (TX) synthesis. Both activities are functionally
distinct and can be clearly distinguished on a number of
chemical criteria. The molecular species responsible for the
stimulation of TX synthesis have been partially identified and
include saturated and monoenoic fatty acids.
Methods
Materials
The synthetic inhibitor of TX-synthase, OKY 046, was from
ONO (Japan). The following reagents and radiochemicals were
also used: [3H] arachidonic acid (166 Cilmmol) from the Centre
d'Etudes Nucldaires (Gil sur Yvette, France); [3H}TXB2 (100
Ci/mmol) from the Radiochemical Centre (Amersham, U.K.);
fatty acids (myristic, palmitic, oleic, stearic) and detergents
(Tween 20, Triton X 100, Lubrol, sodium dodecylsulfate) from
Sigma Chemical Co. (St. Louis, Missouri, USA; silicic acid
(Silicar CC4) from Mallinkrodt Chemical (Paris, Kentucky,
USA); factor Vu—deficient plasma from DADE laboratories,
(Aguada, Puerto Rico); brain thromboplastin (NEOPLASTIN)
from STAGO, (Asnières, France). All solvents were from
Merck Sharp & Dohme (Darmstadt, West Germany).
Cell preparations
Fresh human platelets were obtained using venous blood
from volunteers. Platelet rich plasma was prepared by centrif-
ugation at 100 g for 10 minutes. It was then mixed with buffer A
(10 mM Tris-HC1 buffer, pH 7.5, containing 135 mst NaCI, 10
mM KC1, 10 mM NaCH3COO, 5 mrt glucose) supplemented
with 1 msi EDTA, and was centrifuged at 1,800 g for 10
minutes. After one washing, the final pellet was resuspended in
buffer A.
Human glomeruli were isolated as previously described [5]
from cadaver kidneys judged to be unsuitable for transplanta-
tion. Eight different kidneys were used in this study. Most of
the preparations were obtained from human cortex that had
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been kept at —20°C for less than three months. We had twice
the opportunity to test glomeruli isolated from non-frozen
kidneys which were used less than three hours after their
removal. We studied in parallel freshly—isolated glomeruli and
glomeruli prepared from a sample of cortex which had been
kept frozen for two hours at —20°C and then thawed. The pellet
of isolated glomeruli containing 0.5 to 1.5 mg protein was
resuspended in 500 .d buffer A and incubated at 37°C for 10
minutes. The glomerular suspension was then spun at 1,000 g
for 10 minutes and the cell—free supernatant was used within
three hours.
The protein contents of platelet and glomerular suspensions
were determined according to the method of Lowry et al [6].
Incubation
One hundred d of glomerular supernatant (S) (100 to 300 sg
protein) were either incubated with 100 1.d of buffer at 37°C for
10 minutes or added to 100 1 of platelet (P) suspension (50 to
100 g protein) in the presence of 2 mrs CaCl2. One hundred pi
of control P were incubated in parallel with 100 pi of buffer. The
reaction was stopped by centrifugation at 10,000 g for three
minutes and the supernatants were kept at —20°C for radio-
immunoassay (RIA) of TXB2. In some experiments, glomeruli
were preincubated for 15 minutes at 22°C with either 2 mivi
diisopropylfiuorophosphate (DFP) and 100 lM phenylmethyl-
sulfonylfluoride (PMSF) or with 1 m aspirin. In the latter case
aspirin was eliminated by two washings at the end of the
incubation period. In other experiments, 100 d of dextran
coated charcoal (25 mglml) or 50 p1 of fatty acid—free albumin
(50 mg/ml) were added to 500 p1 of S. Charcoal was then
removed by centrifugation for 15 minutes at 2,500 g and the
charcoal pretreated S or albumin pretreated S was added to P.
Radioimmunoassay (RIA) and radiometric high performance
liquid chromatography (HPLC) of TXB2
RIA was performed according to the technique of Sors et al
[7]. Anti-TXB2 antibody (Institut Pasteur, Paris, France) cross—
reacted less than 0.1% with the other prostaglandins. Fifty
percent inhibition of binding was achieved with 18.5 pg TXB2.
The affinity constant of the antibody was 1.8 io M1. The
smallest detectable concentration of TXB2 was 2.5 pg/mI. The
usual dilutions of the mediums were 1:5, 1:10 and 1:20 for
control P and 1:50, 1:100 and 1:200 for P incubated with the
glomerular supernatant. Dilutions were 1:10, 1:20 and 1:40
when fraction I and exogenous fatty acids were tested. Results
are the means of three values obtained at different dilutions.
TXB2 synthesis was also estimated using radiometric HPLC.
A tracer dose of [3H] AA was added to platelets which were
further incubated at 37°C for 10 minutes. [3H] TXB2 was
extracted and purified as described previously [8].
Effect of exogenous fatty acids
Concentrated solutions in methanol of different fatty acids
(FA) were stored at 4°C (50, 40 and 20 m for myristic, oleic
and stearic acids, respectively). Palmitic acid was stored at 40
m in 1-propanol. FA were incubated separately or in combi-
nation with 250 p1 of control P for 10 minutes at 37°C in the
presence of 2 mivi CaC12. Final concentrations of methanol or
1-propanol in the medium did not exceed 1%. The reaction was
stopped by centrifugation at 10,000 g for three minutes and the
supematants were kept for RIA of TXB2.
Clotting assay
The recalcification time of normal platelet poor plasma (PPP)
was assessed as described by De Prost and Kanfer [1]. Briefly,
100 p1 of PPP were mixed with 100 jsl of S; 100 p1 of 30 ifiM
CaCl2 were then added and the clotting time was recorded.
Preparation of a lipid extract of the glomerular supernatant
S was acidified and treated with methanol ether for lipid
extraction as previously described [91. The aqueous phase was
neutralized with 1 M NaOH and concentrated at 45°C under
nitrogen to its initial volume. One hundred p.1 were then
incubated with platelets to appreciate the TXB2-stimulatory
activity. The dry residue of the organic phase was resuspended
in hexane, ether 90:10 (vollvol). The lipid extract was then
layered on a silicic acid column, (Silicar CC4). The column was
eluted by 15 ml of hexane, ether 90:10 (vollvol) and the solvent
was dried under nitrogen. Recovery of FA estimated by addi-
tion of [3H]oleic acid was nearly total (98%). The fraction
obtained (fraction I), which corresponds to neutral lipids and
fatty acids, was either resuspended in S p1 methanol, then
adjusted to 500 p.1 with buffer A and incubated with 500 1d of P
suspension or analyzed for its free FA content. Thin layer
chromatography (TLC) was performed as a first step analysis.
Kieselgel 60 plates (Merck, Sharp & Dohme) and two different
solvent systems were used: (I) chloroform, methanol, water
65:25:4 (vollvol); (II) first migration in isopropylether—acetic
acid, 96:4 and second migration in petroleum ether, diethyl-
ether, acetic acid 90:30:1 (vol/vol). Spots were revealed by
iodine vapors.
In some experiments, 100 p.1 of dextran-coated charcoal were
added to 500 p.1 of the lipidic extract. Charcoal was then
removed by centrifugation for 15 minutes at 2,500 g and the
charcoal-pretreated extract was added to control P.
Gas chromatography/mass spectrometry (GC/MS)
Quantitative GC-MS estimation of the FA content of fraction
I was achieved by adding arachidic acid (2 p.g) as an internal
standard before lipid extraction. Methylation of FA was ob-
tained by treatment with diazomethane at room temperature for
five minutes and the methylesters were separated by capillary
chromatography (fused silica column, 25 m x 0.32 mm, bound
CPWax 57 CB (Carbowax 20 M), film thickness 0.2 jim). FA
methylesters were detected with maximum sensitivity by mass
spectrometry (Nermag Rb-bC). The chromatograph was run
from 190° to 205°C at the rate of 0.2°C/mm to elute separately
the fatty—acid methyl esters. Identification of eluted peak is
achieved in the electron impact mode (70 eV) by comparison
with a standard library and in the chemical ionization mode
(NH3 as reagent gas) by the [M+ l8] ion.
Results
Effect of the cell—free glomerular supernatant on coagulation
and on platelet TX-generation
The cell—free S obtained after centrifugation of human
glomeruli which had been incubated for 10 minutes at 37°C was
assessed both on the recalcification time of normal plasma and
p+s
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Table 1. Characterization of human glomerular procoagulant activity
Clotting time, sec
Factor
Vu-deficient
Sample Normal human plasma plasma
Buffer A 240 210
Thromboplastin
.(diluted in buffer A) 1:50 291:100 37
190
—
Glomerular supernatant (a) (b)
1:1 45 60
(c) (a)
75 210
(diluted in buffer A) 1:10 60 90
1:100 115 171
140 —
190 —
Protein content of the glomerular suspension is: (a) 4 mg/ml; (b) 2.5
mg/ml; (c) 1.8 mg/mi.
on platelet-TX synthesis, gauged by the level of its stable
metabolite, TXB2. As shown on Table 1, the clotting time of
control human plasma was considerably shortened by the
addition of 100 d of S. This effect was identical to that of
thromboplastin and depended on the amount of S added. S, as
well as thromboplastin, had no effect on the recalcification time
of a human plasma deficient in factor VII, a feature which
characterizes thromboplastinic activity.
The same S added to control P induced a marked increase in
TX-generation. As shown in Figure 1, the experimental sum P
+ S (amount of TXB2 in the experimental tube containing P and
S) was 16-fold higher than the predicted sum P + S (amount of
TXB2 synthesized by P alone + amount of TXB2 present in S;
(P < 0.001, N = 10). No generation of TX was detected when
S was added to P pretreated by 5 JLM OKY 046, a specific
inhibitor of TX-synthase. On the contrary, pretreatment of
glomeruli by aspirin, a drug producing irreversible cyclooxy-
genase inhibition, or by protease inhibitors such as DFP plus
PMSF, did not modify the response of P to S. These results
indicate that the glomerular factor responsible for the increased
platelet-TX synthesis was neither a cyclooxygenase product
nor a proteolytic enzyme. As shown in Table 2, the effect of S
on platelet-TX stimulation was directly dependent on the
amount of S added.
We also compared the results obtained with freshly isolated
glomeruli and glomeruli prepared, as usually, from renal cortex
which had been kept frozen. TXB2 synthesis by P was 1.5 ng/ml
under control conditions (P plus buffer), 24.5 ng/ml in the
presence of S from freshly isolated glomeruli and 28.9 ng/ml in
the presence of S from glomeruli prepared from frozen cortex
(N=2).
Characterization of the platelet-TX stimulating factor
The stimulating factor was thermostabie (100% activity after
3 mm at 100°C) and was still present, although less active, in the
methanol—ether lipid extract of S. No stimulatory activity could
be detected in the aqueous phase. Indeed, there was no
difference between TXB2 production by control platelets (1.44
0.29 ng/mI) and platelets incubated with this aqueous phase
(1.45 0.40 ng/ml; N = 3). After further purification on a silicic
acid column (Methods), the stimulating factor was recovered in
fraction I obtained by elution with hexane—ether (9:1, vol/vol).
Indeed this fraction, after evaporation of the eluent and
Fig. 1. Amounts of TXB2 measured after 10 minutes at 37°C in the
supernatants of human platelets (F), human glomeruli (S), and both
structures incubated in combination (P + S). The predicted sum
indicated by the dashed line is the sum of the amounts of TXB2
generated by P and S separately. It was significantly different from the
experimental sum (P + 5). Means SEM of 10 individual experiments
are given.
Table 2. Dose—dependent effect of the human glomerular supernatant
(S) on the increased synthesis of TXB2 by human platelets
TXB2
Addition ng/ml
None 0.54 0.20 (5)
S undiluted 20.5 3.98 (5)
S diluted 1:2 8.7 3.10 (5)
S diluted 1:4 1.8 0.79 (5)
S diluted 1:8 1 0.45 (5)
S diluted 1:16 0.45 0.24 (4)
Means SEM are given. The number of values is indicated between
brackets.
resuspension of the dry residue in buffer A, still markedly
stimulated TX synthesis in P (Fig. 2) although the degree of
stimulation was strikingly less than with unextracted S. This
decrease was not accounted for by the loss of a part of the
activity during the passage through CC4 column, since stimula-
tory activities of the unpurified lipid extract and fraction I were
not significantly different (mean 7.1 2.3 vs. 8.2 2.7 ng/ml for
total lipid extract and fraction I, respectively). Pretreatment of
P + fraction I
P• 0.005
•1
P
-1-
charcoal - pretroated
fraction I
I I
P
I 'I
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Fig. 2. TXB2 synthesis by human platelets under control conditions
and in the presence offraction I pretreated or not by charcoal. Fraction
I was obtained after extraction and purification of the lipids present in
the supernatant of human G. Means SEM are given. The numbers of
individual values are indicated between brackets. The effect of un-
treated fraction I versus control and versus charcoal—treated fraction I
is significant (P < 0.005).
fraction I with charcoal or FA-free albumin completely sup-
pressed the stimulatory effect. Taken together, these results led
us to hypothesize that the active factor(s) present in S could be
fatty acids and/or neutral lipids, since these compounds repre-
sent the main components of fraction I and are known to be
trapped by charcoal and albumin.
Fraction I was first analyzed by TLC using two different
systems. In system I, only one spot could be seen (Rf 1.00)
comigrating with FA. Because this system doesn't allow the
separation of FA and neutral lipids, we also ran the sample in
solvent system H. In this system, fraction I exhibited several
spots comigrating with cholesterol esters (Rf 0.94), triglyceride
(Rf 0.86), diglyceride (Rf 0.53) and FA (Rf 0.69). No
phospholipids could be detected. Thus, fraction I contained FA
and several other lipid species. However, none of them, except
FA, was able to significantly stimulate platelet-TX synthesis.
We tested cholesterol ester, tripalmitine, oleylacetyiglycerol
and dioleylglycerol. All these products were inactive in the
range 10 to 100 /LM.
Further analysis of fraction I was performed by GC/MS after
methylation, as shown on Figure 3. GC!MS analyis revealed
several long—chain acids, namely myristic, palmitic, stearic and
oleic acids. These fatty acids were identified both by their
retention time on GC and by MS (electron impact fragmentation
(70 eV) or chemical ionization with NH3 as reagent). Remark-
Fig. 3. Fatty acid composition of the stitnula tory fraction (fraction I)
prepared from human glomeruli after lipidic extraction. Fraction I was
dried, methylated and analysed by GC-MS. A representative profile (N
= 3) of the fatty acid composition is shown. The identity of each fatty
acid was confirmed by chemical ionization. Peaks a and b were
identified as phtalates (impurities contaminating vessels and reagents).
No arachidonic acid (C20:4) was detected. Quantitative estimation of
fatty acid was performed using arachidic acid as internal standard (IS).
Abbreviations are: C14:0, myristic acid; Cl6:0, palmitic acid; C18:0,
stearic acid; C18:l, oleic acid; C18:2, linoleic acid.
ably, no AA was detected by GC/MS in fractions I obtained
from three different samples. This excluded the possibility that
exogenous AA from glomerular origin was the agent responsi-
ble for the increase in TX synthesis. In contrast, substantial
amounts of myristic, stearic, palmitic and oleic acids were
found. Using arachidic acid as an internal standard the total
concentration of these FA in fraction I was estimated to be
around 80 rM with the following order of abundance: stearic
acid (40 ELM), palmitic acid (26 sM), myristic acid (10 M) and
oleic acid (8 M) (mean of two experiments).
Effect of exogenous synthetic fatty acids on TX synthesis in
platelets
Control P were exposed to the combination of the four FA
identified in fraction I. Their respective concentrations were
chosen in accordance with both their endogenous level and
their solubility (125 M myristic, 100 sM palmitic, 100 sM
stearic and 10 jM oleic acids for the maximum total concentra-
tion tested). As shown in Figure 4A, a fivefold increase in TX
generation was obtained under these conditions (total FA
concentration of 335 LM). This effect was dose—dependent and
the lowest dose studied (40 ILM) still significantly stimulated TX
synthesis in P (P < 0.05). The presence of the four FA in the
mixture was not essential since omission of palmitic acid, one of
the major components of fraction 1, and its replacement by a
supplement of oleic acid also resulted in dose—dependent stim-
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Fig. 4. TXB2 synthesis by human platelets was measured under the
following conditions: (A) at increasing concentrations of the mixture of
fourfatty acids; (B) at increasing concentrations of the mixture of three
fatty acids; (C) at increasing concentrations of myristic acid; (D) with
three fatty acids in combination or each of them separately. M, myristic
acid; S, stearic acid; 0, oleic acid; F, palmitic acid. Means SEM Of 5
to 7 individual values are given.
ulation of TX synthesis (Fig. 4B). Moreover, myristic acid
tested individually at 400 /LM also increased TX synthesis (Fig.
4C). Nevertheless, the stimulation obtained was significantly
lower (P < 0.05) than that observed with the combination of
three FA studied at the same total concentration. The stimula-
tory effect of mynstic acid was also dose—dependent. Of the
three FA tested separately at 400 M, myristic acid was the
most effective to promote stimulation of TX synthesis (300%
increase vs. 40% for palmitic and 227% foroleic acids) probably
because of its greater solubility. Finally, it appeared that
combination of three FA provided a synergistic effect (Fig. 4D).
Indeed, the amount of TXB2 produced under stimulation by the
mixture was greater than the sum of the individual amounts of
TXB2 produced in the presence of each FA tested separately at
the same concentration than that used in the mixture.
In order to exclude that fatty acids could act as non-specific
detergents, we also studied the effect of four different deter-
gents. TXB2 synthesis was measured both by RIA and
radiometric HPLC because these agents interfere with the
antigen—antibody reaction, which results in high blank values
when RIA is used. There was a strong inhibition of TXB2
production by platelets in the presence of each of the detergents
studied (Table 3). Therefore, these results suggest that the
effect of fatty acids on TXB2 synthesis in platelets is indepen-
dent of their detergent properties.
Biochemical criteria allowing distinction between PCA and
TX stimulating activity
Although both present in S, the two activites (PCA and TX
stimulating activity) were clearly chemically different and could
be separated on several grounds (Table 4): i.) pretreatment of S
by charcoal or albumin did not affect PCA but abolished
TX-stimulating activity; ii.) centrifugation for 60 minutes at
105,000 g totally suppressed PCA whereas TX-stimulating
activity was still present, although less potent; iii.) the lipid
extract of S still contained the TX-stimulating activity but was
deprived of PCA. Thus, although released together, these two
activities are functionally and chemically distinct. PCA which is
supposed to be a lipoprotein, sediments at 105,000 g and is not
affected by charcoal or albumin treatment. In contrast, the
TX-stimulating activity includes several identified long—chain
saturated or monoeinoic fatty acids which are totally adsorbed
on charcoal or FA-free albumin.
Discussion
The data presented here clearly demonstrate that human
glomeruli release a diffusible factor which strongly stimulates
P-TX synthesis. This factor has not been fully identified and is
likely to include several components. Using GCIMS we have
been able to demonstrate that at least a part of the stimulatory
activity was composed of saturated and monoenoic FA. This
conclusion is supported by the following observations: i.) the
cell—free S obtained after incubation of glomeruli in buffer
stimulated TX-synthesis in P in a dose—dependent manner; ii.)
fraction I prepared by purification of the lipid extract of S
resulted in a similar, although less potent, stimulatory effect.
This effect was suppressed by pretreatment of fraction I by
charcoal or albumin; iii.) analysis of fraction I by GC/MS
revealed the presence of approximately 80 LM of FA which
were identified as myristic, palmitic, stearic and oleic acids. In
contrast there was no detectable amount of AA. The latter
result excludes the possibility that glomeruli released free AA
serving as a substrate for TX synthase in P; iv.) exogenous
addition to P of the four FA which were detected in fraction I
reproduced the stimulation of TX-synthesis observed with
fraction I itself. Stimulation was also dose—dependent and was
significant, although of a smaller degree, at the concentration
corresponding to the endogenous levels.
The hypothesis that collagen or proteolytic enzymes from
glomerular origin might be present in fraction I and contribute
to TX-stimulation can be excluded. Collagen and proteolytic
enzymes are not extracted by organic solvents and thus, would
not have been present in fraction I. In addition, pretreatment of
S with serine protease inhibitors such as DFP and PMSF as well
as ebullition for 3 minutes did not decrease its stimulatory
potency. Platelet activating factor cannot be either incriminated
since unstimulated human glomeruli do not produce PAF-
acether (results not shown). Furthermore, PAF-acether would
not elute in fraction I but would need a more polar eluent such
as methanol.
FA do not represent the unique stimulus present in S because
stimulation of P by S was markedly greater than that obtained
with the lipid extract of S. In order to precise what were the
other components of the stimulatory activity, we tested the
different fractions obtained during the purification process.
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Table 3. Effect of detergents on platelet-TXB2 formation
Triton SDS Tween 20
% %
Lubrol
%
RIA determination of TXB2
Detergent concentration 0.3 0.6 1.2 50 100 200 0.1 0.2 0.5 0.25
Percent of inhibition 69 79 100 82 95 93 0 50 75 50
Percent inhibition was calculated by comparing TXB2 levels in platelets exposed to detergents or exposed to buffer alone.
Radiometric HPLC: [3H] TXB2 (cpm/tube)
P P + giomerular S P + 200 M SDS P + 1.2% triton
Exp. 1 20,145 98,213 1,206 4,825
Exp. 2 31,112 112,048 9,858 7,960
Results are expressed as cpm of [3H] TXB2 recovered after HPLC purification. A tracer dose of [3H] AA (32 ng/ml) was added to P exposed or
not to detergents or to the glomerular supernatant. Two experiments were performed.
Table 4. Differential properties of procoagulant activity (PCA) and
platelet-TX stimulating activity present in the glomerular supernatant
Pretreatment of the
cell—free supernatant PCA
Platelet-TX
stimulating activity
None + +
Charcoal 25 mg/mI + —
Fatty—acid free albumin 50 mg/mi + —
Centrifugation at 105,000 g for 60 mm —
Lipid extract of the supernatant — +
The recalcification time of normal plasma and TX-synthesis by
control platelets were determined as described in Methods. The effect
of a pretreated vs control supernatant was tested on these two activi-
ties. Presence of PCA or platelet—stimulating activity at a level identical
to that of the control supernatant was noted (+). Absence of activity
was noted (—). Activity present, but lower than control S, was noted
First, we found that the aqueous phase remaining after lipid
extraction was devoid of any stimulatory activity. Second, we
showed that there was no loss of fatty acids during extraction.
Third, we also showed that the passage through the silicic acid
column did not account for the loss of activity. Taken together,
these results suggest that, in addition to the stable component
present in fraction I, there was also a labile component which
disappeared during the purification process. This latter compo-
nent could be a thermostable factor yet unidentified, perhaps a
lipoprotein, which would be destroyed by acidification and
methanol precipitation.
It remains to explain why synthetic FA exogenously added
were less potent than fraction I itself since TLC analysis
demonstrated that FA represented the main component of
fraction I. One interpretation could be that we performed a
great number of experiments for fraction I activity (N = 11)
whereas we quantitatively analyzed only two preparations by
GC/MS. Therefore, the concentration of FA we found (80 jiM)
is perhaps underestimated and not representative of the real
amount present in the nine other experiments. An other inter-
pretation is that the presence of various other lipids might favor
the action of FA on platelets. Anyway this yet unsolved
problem seems to be not essential. It does not preclude our
main conclusion that the same FA which are present in S
activate TXB2 synthesis in platelets.
The mechanism by which P could be stimulated by saturated
fatty acids is still unknown. Any increase in the delivery of AA
inside P would promote stimulation of TX synthesis. Glomeru-
lar saturated FA might directly stimulate phospholipase A2
(PLA2) although a recent report by Ballou and Cheung [101 does
not argue in favor of this hypothesis. These authors reported
inhibition of PLA2 purified from human P in the presence of a
monoenoic FA such as oleic acid and no effect of stearic acid.
Glomerular FA might also stimulate phospholipase C (PLC).
Activation of PLC also leads to AA release in P [11], indirectly
activates protein kinase C via the release of diglyceride and
plays a major role in P aggregation [12]. Several data from the
literature emphasize the role of lipids as activators of enzymes
involved in AA metabolism: long—chain fatty acids such as
linoleic and oleic acids stimulate Ca k-dependent protein
kinase C in human neutrophils [13] and other lipidic activators
of protein kinase C such as phorbol myristate acetate and
diacylglycerol enhance the activity of PLA2 through phospho-
rylation and inactivation of lipocortin or other related proteins
[14, 15]. Like other detergents, FA in the concentration range of
10 to 100 jiM could also modify phospholipids in P membranes
and render them more susceptible to be activated by PLC, a
mechanism recently advanced by Dawson et al [16]. In fact this
hypothesis can be excluded in the present study since different
detergent agents produced a decrease in TXB2 production in
platelets in opposition with the stimulatory effect of saturated
fatty acids. A more likely hypothesis has been recently ad-
vanced. Proteins may be activated by the same saturated and
monoenoic FA as those we have found in S. Mouse submaxil-
lary gland renin is stimulated by three of these FA (such as
myristic, palmitic and stearic acids) [17], phosphodiesterase
and ATPase by oleic acid [18]. Protein activation depends on
acylation of the proteins. Olson, Towler and Glaser [19] and
Towler and Glaser [20] have demonstrated that [3H] myristate
or [3H] palmitate covalently bound to proteins. Moreover, the
myristoylation is specific as shown by Aderem et al [21] for the
macrophage proteins and may be induced by stimuli of arachi-
donic acid metabolism such as zymosan and phorbol myristate
acetate.
The cellular source of the identified FA in S is uncertain.
These were essentially saturated FA. The hydrolytic cleavage
of saturated or monoenoic FA from position 1 of phospholipids
might reflect the glomerular cellular lesions produced during
sample preparation. In addition, PLA1, lysophospholipases or
lipases could equally play a role in the release of these saturated
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FA which are the major substituants of phospholipids in posi-
tion 1 [221.
The present results also demonstrate that human glomeruli,
like rat glomeruli, release PCA. This activity has been observed
in the cell—free supernatant obtained from glomeruli mechani-
cally prepared from frozen human renal cortex. Thus PCA may
be released without total cell disruption but only after minor
alterations of cell membranes such as those occurring during
glomerulonephritis.
In conclusion, it appears that human glomeruli release a
number of factors which are involved in the control of
intracapillary hemostasis. Some of them prevent intracapillary
coagulation, such as the tissular plasminogen activator from
endothelial origin and urokinase from epithelial origin [23].
Others such as PCA or the new factor identified here as
saturated FA might contribute to the formation of intracapillary
deposits of fibrin. Damage of the glomerular endothelium or
other glomerular cells could thus activate P functions indepen-
dently of collagen and result in the local accumulation of TXA2.
The toxic role of this prostanoid in several models of experi-
mental glomerulonephritis has been recently inferred from the
beneficient effect of TX synthesis inhibitors on glomerular
function [24], hemodynamics [25] and proteinuria [261. More-
over, TXA2 produces in vitro a decrease in the surface area of
mesangial cells which is probably responsible for its effect on
glomerular filtration rate [271. By promoting local TXA2 gener-
ation, FA might be actively involved in the glomerulonephritis
process.
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